EKSO BIONICS HOLDING (OTCBB:EKSO) disclosed that Amy Wendell who is former Senior VP of “Strategy and Business Development” segment of Covidien plc (NYSE:COV) has been elected to its Board. Nathan Harding, the CEO and Co-founder stated that Amy Wendell in her last association with Covidien had a successful record of acquisition plans acquiring more than hundred firms with advance technologies in healthcare segments.
Wendell has designed, executed and succeeded in various growth plans. She understands the dynamics of the market and plans the strategies that make sense. EKSO Bionics looks forward to benefit from her experience and expertise in healthcare field.
The expert speaks
Steven Sherman, the Chairman of EKSO BIONICS stated that the company was committed to elect a board member with all the prominent qualities that Wendell reflects for more than a year now. The company’s management welcomes such an experienced individual on the board. Sherman further said that he is confident Wendell will significantly contribute in the growth of the company.
Talking about the recent association, Wendell stated that she had always had keen interest in medical device technology. She had and will like to lead innovative firms to make a positive impact in people’s lives. The objective is to help the companies achieve their business milestones and enter into new markets. Wendell further said that she is thrilled to notice by what EKSO has started to accomplish.
Wendell has served on different leadership profiles at Covidien. She led the portfolio management activities and strategic planning operations. She even looked after various business development activities like M&A, distribution, licensing, market intelligence, equity investments, integrations and divestitures. After the addition of Wendell, the size of board has increased to seven.
On Friday’s trading session, the stock price of EKSO surged more than 1% to close the trading session at $1.97. The gains came at a share volume of 349,971 much lower than average volume of 1 million.